23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
1 June 2016. Related: Conference reports.
CROI 23 (Retrovirus) 2016
No effect of tenofovir on infant bone mineral content in African study
1 June 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Use of modelling to predicting paediatric dosing of long acting antiretrovirals
1 June 2016. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Nevirapine dosing for treatment of neonates
1 June 2016. Related: Conference reports, Paediatric care, PK and drug interactions.
START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers
1 June 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV
1 June 2016. Related: Conference reports, Hepatitis coinfection.
23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston
22 March 2016. Related: Conference reports.
Dual long-acting injections of cabotegravir plus rilpivirine: 32-week results from LATTE-2 study
22 March 2016. Related: Conference reports, Antiretrovirals.
New NRTI MK-8591 (EFdA): weekly oral dosing and once-yearly slow-release dosing has potential for HIV treatment and PrEP
22 March 2016. Related: Conference reports, Antiretrovirals.
48-week results for NNRTI doravirine compared to efavirenz
22 March 2016. Related: Conference reports, Antiretrovirals.
Dramatic increase in use of oral TDF/FTC for PrEP in the US – plus a few cautions
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Future oral and long-acting formulations for PrEP: pills, films, gels, injections and depots
22 March 2016. Related: Conference reports, HIV prevention and transmission.
First data on TAF as PrEP to prevent HIV infection
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Long-acting cabotegravir as PrEP protects macaques against IV exposure but will need two-monthly injections
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Role for maraviroc as HIV PrEP likely to need dual combinations
22 March 2016. Related: Conference reports, HIV prevention and transmission.
Dapivirine PrEP vaginal ring shows only limited PrEP protection against HIV in African women
22 March 2016. Related: Conference reports, HIV prevention and transmission, Vaccines and microbicides.
Early data from dolutegravir use during pregnancy
22 March 2016. Related: Conference reports, Pregnancy.
Dolutegravir: 48 week results in children age 6 to 12 years old
22 March 2016. Related: Conference reports, Paediatric care.
New antiretrovirals could mean savings up to US $3 billion by 2025
22 March 2016. Related: Conference reports, Treatment access.
Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Nigerian herbal medicines widely used by HIV positive people can contain antiretrovirals
22 March 2016. Related: Conference reports, Antiretrovirals.
Cure research news from CROI 2016
22 March 2016. Related: Conference reports, Cure-related research.